Liver Cirrhosis: Causes, Symptoms, and Stages of the Disease

This shift in the underlying causes has practical implications: while the number of hepatitis-B-related cirrhosis cases keeps falling steadily (thanks partly to vaccination and antiviral drugs), cirrhosis linked to nonalcoholic fatty liver disease is rising in step with the global obesity and type 2 diabetes epidemic — a phenomenon we cover in more detail in a separate article on nonalcoholic fatty liver disease (NAFLD/MASLD).

In the early stage, known as compensated cirrhosis, the liver — despite progressive fibrosis — is still able to carry out most of its functions at a level sufficient to maintain the body's homeostasis. This is exactly what makes this stage insidious: the absence of obvious symptoms means diagnosis is often delayed, and the disease is frequently discovered incidentally, during blood tests or imaging done for an entirely different reason.

Even at this stage, nonspecific symptoms can appear — chronic fatigue, weakness, or discomfort under the right ribs — but they're general enough to be easily attributed to other, less serious causes. That's why regular check-ups in people with known risk factors — rather than waiting for obvious symptoms to appear — are key to early detection.

Cirrhosis itself — the permanent replacement of liver tissue with scar tissue — isn't a fully reversible process, but early detection of the underlying disease and consistently treating its cause can significantly slow fibrosis progression and, for some patients, prevent or delay decompensation. This is especially true for causes that can genuinely be influenced: weight loss for cirrhosis related to NAFLD/MASLD, complete abstinence for alcohol-related disease, antiviral treatment for hepatitis B and C, or immunosuppressive therapy for autoimmune diseases.

This distinction — between the irreversibility of the scar tissue itself and the ability to halt further disease progression — is key to a realistic understanding of what to expect from treatment. The therapeutic goal in a patient diagnosed with cirrhosis is rarely to 'reverse' the disease back to a healthy liver, and almost always to halt or maximally slow further damage and prevent complications.

Liver cirrhosis is still too often seen as a disease with one cause and one type of patient — but global epidemiological data show a far more complex picture, in which nonalcoholic fatty liver disease has now moved into first place among causes. This changes how prevention should be approached: weight control, managing diabetes, and regular liver tests are becoming just as important a part of preventing cirrhosis as limiting alcohol consumption.

The distinction between compensated and decompensated stages is key — not because one of them 'doesn't need attention,' but because understanding this distinction helps explain why regular monitoring in people with risk factors makes sense well before obvious symptoms appear, rather than only after the first serious complication occurs.